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pluripotency?Available online 10 August 2015The advent of induced pluripotent stem cells (iPSCs)
marked a giant step forward towards the reality of con-
verting one type of primary somatic cells into different
lineages capable of clinically repairing damaged tissues and
organs. However, the major drawbacks of iPSCs hinder their
quick translation to the bedside. These drawbacks include
the time-, cost-, and labor-intensive process in production
of clinical products from iPSCs, and the inherent risk of
long-term tumorigenesis due to the forced expression of
transcription factors associated with pluripotency, which
are often implicated as aberrations within the cancerous
gene circuitry.
The recent reports of the direct conversion of one so-
matic lineage into other types following a short-term pulse
of pluritotent transcription factors pointed to a more effi-
cient and more lineageeversatile alternative to those using
only lineage-restricted transcription factors.1,2 This new
approach has also been applauded for its perceived safety
merits due to need for fewer perturbations of the genes in
the target cells and, perhaps, without generating “true”
iPSCs. However, the question remains whether this short-
term approach represents a mechanistically different
method, which avoids the total erasure of restricted
epigenetic imprints as does iPSCs generation, and whether
it therefore bypasses the pluripotency stage.3,4 Two recent
articles published in the same issue of Nature Biotech-
nology offered some definitive answers.5,6 Using different,
but reliable lineage tracing methods, the two groups of
scientists came to the same conclusion that the majority of
the converted new lineage offspring cells did indeed come
from the intermediate precursors reprogrammed throughPeer review under responsibility of Chongqing Medical
University.
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cursors bear the genomic and proteomic hallmarks, as well
as having biological properties, similar to those found in
iPSCs. Although the short-term approach still has its merits
of efficiency and simplicity when generating desired so-
matic lineages for research and clinical application, these
fresh insights will certainly shape the guidebook for its
clinical translation, which requires that the risk of tumori-
genesis be examined with the same rigor as in the case of
iPSC-derived lineage cells.
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